Par Drugs and Chemicals Limited (IN:PAR)
:PAR
Want to see IN:PAR full AI Analyst Report?
PAR Stock Chart & Stats
₹100.93
-₹2.28(-1.11%)
At close: 4:00 PM EST
₹100.93
-₹2.28(-1.11%)
Day’s Range― - ―
52-Week Range₹78.05 - ₹122.43
Previous CloseN/A
Volume42.53K
Average Volume (3M)31.06K
Market Cap
₹1.12B
Enterprise Value₹781.90M
Total Cash (Recent Filing)₹338.56M
Total Debt (Recent Filing)₹0.00
Price to Earnings (P/E)6.5
Beta0.92
Next Earnings
May 07, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)3.90
Shares Outstanding12,304,636
10 Day Avg. Volume60,109
30 Day Avg. Volume31,062
Financial Highlights & Ratios
PEG Ratio-1.02
Price to Book (P/B)1.08
Price to Sales (P/S)1.06
P/FCF Ratio7.14
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Balance Sheet StrengthZero reported debt provides durable financial flexibility and low solvency risk; it allows the company to fund operations, capex or working capital from internal resources, pursue opportunistic M&A or absorb revenue shocks without stressing leverage over the next 2–6 months.
Equity Growth & ROESteady equity accumulation and mid-teens ROE indicate consistent retained earnings and efficient capital allocation. This builds a larger internal capital base to support product investment and scale, improving resilience and ability to finance growth without external debt.
Consistent Free Cash FlowAnnual positive free cash flow, with FCF ~₹149M in FY2025 and OCF ~0.98x net income, shows reliable cash generation. Durable cash conversion supports reinvestment, working capital needs and cushions earnings volatility, enabling sustained operations and optional shareholder returns.
Bears Say
Sharp FY2025 Revenue DeclineA ~48% revenue drop materially reduces scale, can erode bargaining power and leave fixed costs under-absorbed. If demand or contract issues persist, topping up lost volume will pressure medium-term margins and slow recovery of sustainable growth over the next several quarters.
Earnings VolatilityDeclining net income and fundamentals EPS growth negative (~-9.9%) point to profitability instability. Even with solid gross margins, earnings swings hamper predictable cash available for reinvestment or dividends and raise execution risk for maintaining long-term strategic initiatives.
Cash Conversion & Liquidity DisclosureFluctuating operating cash conversion across years and limited liquidity detail in filings reduce transparency on short-to-medium term cash buffers. That increases risk the firm may need external financing if revenue weakness persists, weakening financial resiliency despite zero debt.
Par Drugs and Chemicals Limited News
PAR FAQ
What was Par Drugs and Chemicals Limited’s price range in the past 12 months?
Par Drugs and Chemicals Limited lowest stock price was ₹78.05 and its highest was ₹122.43 in the past 12 months.
What is Par Drugs and Chemicals Limited’s market cap?
Par Drugs and Chemicals Limited’s market cap is ₹1.12B.
When is Par Drugs and Chemicals Limited’s upcoming earnings report date?
Par Drugs and Chemicals Limited’s upcoming earnings report date is May 07, 2026 which is in 8 days.
How were Par Drugs and Chemicals Limited’s earnings last quarter?
Par Drugs and Chemicals Limited released its earnings results on Feb 10, 2026. The company reported ₹3.899 earnings per share for the quarter, beating the consensus estimate of N/A by ₹3.899.
Is Par Drugs and Chemicals Limited overvalued?
According to Wall Street analysts Par Drugs and Chemicals Limited’s price is currently Overvalued.
Does Par Drugs and Chemicals Limited pay dividends?
Par Drugs and Chemicals Limited pays a Notavailable dividend of ₹1.25 which represents an annual dividend yield of N/A. See more information on Par Drugs and Chemicals Limited dividends here
What is Par Drugs and Chemicals Limited’s EPS estimate?
Par Drugs and Chemicals Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Par Drugs and Chemicals Limited have?
Par Drugs and Chemicals Limited has 12,304,636 shares outstanding.
What happened to Par Drugs and Chemicals Limited’s price movement after its last earnings report?
Par Drugs and Chemicals Limited reported an EPS of ₹3.899 in its last earnings report, beating expectations of N/A. Following the earnings report the stock price went up 0.187%.
Which hedge fund is a major shareholder of Par Drugs and Chemicals Limited?
Currently, no hedge funds are holding shares in IN:PAR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Par Drugs and Chemicals Limited
Par Drugs and Chemicals Limited develops, produces, and sells active pharma ingredients and fine chemicals in India. It offers magnesium salts, dried aluminum hydroxide gel, sodium aluminum silicate, precipitated silica, magnesium silicate, colloidal silicon dioxide, sucralfate USP, and amorphous and blended products. The company also exports its products. Par Drugs and Chemicals Limited was founded in 1982 and is based in Vadodara, India.
Technical Analysis
Balaxi Pharmaceuticals Limited
―
Bal Pharma Limited
―
Biofil Chemicals & Pharmaceuticals Ltd.
―
―
Vaishali Pharma Ltd.
―